After 24 or 48 h of treatment with HER2-targeted chemotherapies, cell viability was measured in the HER2-positive BT 474 breast cancer cell line (Figure 2A) and the triple-negative breast cancer cell line HC 1806 (Figure 2B). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.